The enterprise apps · credentialed by ABOPM

NEXes are enterprise learning ledgers credentialed by ABOPM.

The governance triad applies to any specialty: AnkiNex is the education ledger, CaseNex is the clinical ledger, OmicsNex is the research ledger. The three converge on a specialty orchestrator — OncoNex for oncology, with parallel siblings (CardioNex, NephroNex, NeuroNex, …). Every credentialed write hash-chains; LAUDE federates the three ledgers into one signed molecular signout. The patient-facing chats — MammoChat and its cultural derivatives — are the free community learning ledger on the next slide.
On
OncoNex
enterprise · case-001
Enterprise
9:415G   100%
An
Enterprise
AnkiNexcommunity
18
cards
0.72
top diff
62%
miss rate
OncoNex · 4:02 PMCohort difficulty on BRCA1 c.5266dupC. Tumor board in 28 min.
LAUDE · cards.cohort_signal()18 faculty cards in HBOC + Caribbean cohort. Top difficulty 0.72 on PI3K/AKT/mTOR mechanism.
cohort_signal
cards18 / 22
top diff0.72 (hot)
miss rate62% PI3K
cohortHBOC+Carib
Why so hard? Where are learners snagging?
LAUDE62% conflate PVS1 (null variant) with PVS1_strong evidence weight. Richards 2015 §5.1.
LAUDE · 4:03 PMANKI_DIFFICULTY_SIGNAL from Marcus (MS3) last night, this exact card.
Pin #17 for the fellows' prep deck.
LAUDEPinned. ANKI_CARD_BOOSTED emitted. +14d priority.
Tag for the fellow rotation?
LAUDE · 4:04 PMTagged HBOC-Carib-fellow-prep. 4 fellows on rotation will see it on Monday.
LAUDE is composing the next 3 cards…
AnkiNex answer
18 cards · top diff 0.72 · 62% miss PI3K/AKT/mTOR
9:415G   100%
Cs
Enterprise
CaseNexpeer-signed bundles
case-001
bundle
2/2
signed
+5
COIN
OncoNex · 4:02 PMCase-001 bundle. Signature chain + cohort tag before I open the board.
LAUDE · case.pull(case-001)Peer-signed @anil + @irman, Tier-1A.
signature chain
@anilCO-SIGN ✓
@irmanPEER-SIGN ✓
hashad9c3b2…
tier1A
cohortsouth-fl-carib-seph
LAUDE · cohort.gap_check()3rd Cuban-Sephardic carrier in 14 mo at MSMC. Zero published cohorts on this admixture. case-001 fills the gap on publish.
Embed Toronto surveillance so the daughter inherits.
LAUDEAttached. CASCADE_PROTOCOL_LINKED. Daughter's subtree now references this bundle.
Sign-ready for the board?
LAUDE · 4:04 PMYes. Open-read public on CASE_PUBLISHED. COIN +5 mints to @anil + @irman.
Open the board view.
LAUDEOpening tumor-board-protocol-014. Bundle attached. TUMOR_BOARD_VIEW_OPENED emitted.
CaseNex answer
Tier-1A · @anil + @irman · 3rd carrier · gap-filling
9:415G   100%
Om
Enterprise
OmicsNexvariant interpretation
7×
anchors
PATH
verdict
1A
PARP-i
OncoNex · 4:02 PMPathogenicity on c.5266dupC. ACMG + functional + drug response. Tight.
LAUDE · variant.pull_anchors()7 anchors federated:
anchor table
ClinVarVCV055638 · 4★
ClinGen ENIGMAVCEP v1.1.0
COSMICtumor profile
gnomAD v4.1AFR 0.0008
F1CDxHRD+ 48%
CPICPARP-i 1A
Findlay SGE−1.68 LOF
LAUDEFunctional: Findlay SGE −1.68 (LOF → PS3). ACMG: PVS1 + PS3 + PM2_S + PP5 → Pathogenic.
Olaparib first-line. Tamoxifen safety for the daughter (TP53+)?
LAUDE · CPIC.tamoxifen.contraindicationsDaughter only. Tamoxifen + RT contraindicated on TP53. Mother stays on olaparib. Cross-flag emitted to tumor-board.
Lock in. CASE_CLASSIFY.
LAUDE · 4:03 PMLocked. CLASSIFY + ANCHOR_CITED ×7 fired.
Push to peer-sign queue.
LAUDEQueued for @irman + @anil. ETA ~10 min based on their typical sign cadence.
OmicsNex answer
Pathogenic · PVS1+PS3+PM2_S+PP5 · PARP-i Tier-1A
↓cohort signal
↓case bundle
↓variant anchors
OncoNex
synthesizes
Case-001 tumor-board signout: Pathogenic BRCA1 c.5266dupC · PARP-i Tier-1A · Toronto Protocol for daughter's TP53 R175H. Three ledgers, three answers, one signed protocol. Same pattern reused by CardioNex, NephroNex, NeuroNex — only the orchestrator changes.
TUMOR_BOARD_
PROTOCOL_SIGNED
CANONIC Nexus
For providers. Enterprise ledgers, credentialed by ABOPM.
SLIDE ?? / ??